Medgirl131: ←Created page with ''''Corticosteroid-induced lipodystrophy''' is a condition of abnormal fat deposition caused by corticosteroid medications.<ref name="pmid17...'
'''Corticosteroid-induced lipodystrophy''' is a condition of [[lipodystrophy|abnormal fat deposition]] caused by [[corticosteroid]] medications.<ref name="pmid17867724">Liquid error: wrong number of arguments (1 for 2)</ref> Fat accumulates in the facial area ("[[moon face]]"), dorsocervical region ("buffalo hump"), and abdominal area ("pot belly" or "beer belly"), whereas the thickness of [[subcutaneous fat]] in the limbs is decreased.<ref name="pmid17867724" /> The resulting appearance has been described as "Cushingoid",<ref name="pmid17867724" /> in relation to the fact that it also occurs in individuals with [[Cushing's syndrome]].<ref name="pmid27177728">Liquid error: wrong number of arguments (1 for 2)</ref> The condition is considered by patients to be the most distressing side effect caused by corticosteroids.<ref name="pmid17867724" />
Short-term therapy (<3 months) with 10 to 30 mg/day of a [[prednisone]] equivalent has been reported to be associated with Cushingoid traits in 15 to 40%.<ref name="pmid17867724" /> Long-term therapy (>3 months) with corticosteroids has been associated with Cushingoid features in 32 to 83% of individuals.<ref name="pmid17867724" /> However, these symptoms have mostly been diagnosed in a subjective and observer-dependent manner.<ref name="pmid17867724" /> In a prospective study, the cumulative incidence of corticosteroid-induced lipodystrophy with high-dose prednisone therapy was found to be 61% after 3 months, 65% after 6 months, 68% after 9 months, and 69% after 12 months.<ref name="pmid17867724" /> One study found that even a very low dosage of prednisone of 5 mg/day was associated with symptoms of "Cushing's syndrome".<ref name="pmid17867724" /> It has been said that data on risk factors for corticosteroid-induced lipodystrophy, such as corticosteroid dosage or duration of therapy, is surprisingly sparse.<ref name="pmid17867724" /> Possible risk factors for corticosteroid-induced lipodystrophy include high residual cortisol secretion, decreased clearance of corticosteroids, female sex, younger age (<50 years), high initial [[body-mass index]], and high [[caloric intake]].<ref name="pmid17867724" />
Corticosteroid-induced lipodystrophy has been found to be usually reversible at prednisone-equivalent dosages of less than 10 mg/day.<ref name="pmid17867724" /> A [[low-calorie diet]] may be considered to limit the risk of corticosteroid-induced lipodystrophy or to attempt to reverse it.<ref name="pmid17867724" /> Corticosteroid-induced lipodystrophy is not merely an aesthetic adverse effect, as it has been associated with features of [[metabolic syndrome]] such as [[insulin resistance]], [[dyslipidemia]], and [[high blood pressure]].<ref name="pmid17867724" />
==See also==
* [[Steroid dementia syndrome]]
* [[Steroid diabetes]]
* [[Steroid-induced osteoporosis]]
* [[Steroid induced skin atrophy]]
==References==
[[Category:Corticosteroids]]
[[Category:Cutaneous conditions]]
Short-term therapy (<3 months) with 10 to 30 mg/day of a [[prednisone]] equivalent has been reported to be associated with Cushingoid traits in 15 to 40%.<ref name="pmid17867724" /> Long-term therapy (>3 months) with corticosteroids has been associated with Cushingoid features in 32 to 83% of individuals.<ref name="pmid17867724" /> However, these symptoms have mostly been diagnosed in a subjective and observer-dependent manner.<ref name="pmid17867724" /> In a prospective study, the cumulative incidence of corticosteroid-induced lipodystrophy with high-dose prednisone therapy was found to be 61% after 3 months, 65% after 6 months, 68% after 9 months, and 69% after 12 months.<ref name="pmid17867724" /> One study found that even a very low dosage of prednisone of 5 mg/day was associated with symptoms of "Cushing's syndrome".<ref name="pmid17867724" /> It has been said that data on risk factors for corticosteroid-induced lipodystrophy, such as corticosteroid dosage or duration of therapy, is surprisingly sparse.<ref name="pmid17867724" /> Possible risk factors for corticosteroid-induced lipodystrophy include high residual cortisol secretion, decreased clearance of corticosteroids, female sex, younger age (<50 years), high initial [[body-mass index]], and high [[caloric intake]].<ref name="pmid17867724" />
Corticosteroid-induced lipodystrophy has been found to be usually reversible at prednisone-equivalent dosages of less than 10 mg/day.<ref name="pmid17867724" /> A [[low-calorie diet]] may be considered to limit the risk of corticosteroid-induced lipodystrophy or to attempt to reverse it.<ref name="pmid17867724" /> Corticosteroid-induced lipodystrophy is not merely an aesthetic adverse effect, as it has been associated with features of [[metabolic syndrome]] such as [[insulin resistance]], [[dyslipidemia]], and [[high blood pressure]].<ref name="pmid17867724" />
==See also==
* [[Steroid dementia syndrome]]
* [[Steroid diabetes]]
* [[Steroid-induced osteoporosis]]
* [[Steroid induced skin atrophy]]
==References==
[[Category:Corticosteroids]]
[[Category:Cutaneous conditions]]
from Wikipedia - New pages [en] http://bit.ly/2EV2OLM
via IFTTT
No comments:
Post a Comment